News

ZAS Corporation proudly announces the official launch of its DECA® series of sterile surgical gloves, marking a significant milestone in advancing surgical safety, comfort, and skin protection. The launch event, themed “Launch & Lead with DECA”, was held at a picturesque resort and brought together our dedicated team, esteemed partners, and industry leaders in a

ZAS Corporation recently held a strategic business overview meeting with its esteemed global partner, Celltrion from Korea. The session focused on sharing insights, aligning future plans, and exploring new opportunities for growth. Both teams discussed the current business landscape and reaffirmed their commitment to delivering innovative solutions together. This collaboration continues to reinforce ZAS Corporation’s

ZAS Industries proudly announces the launch of a new range of premium wound care products from Pharmaplast, a global leader in wound care and cosmetic solutions. With a shared commitment to delivering quality and patient-focused innovations, this launch marks a significant step in advancing wound management standards in the local market. The newly introduced products

ZAS Corporation is proud to collaborate with the Rheumatology Department of BIRDEM General Hospital to introduce three world-class biosimilar therapies from Celltrion Healthcare, Korea—Yuflyma® (adalimumab), Truxima® (rituximab), and Remsima® (infliximab).The initiative was formally marked at a recent CME event, where Dr. Sabrina Yesmin, Associate Professor & Head of the Rheumatology Department, shared her expert insights

ZAS Corporation Ltd. was honored to take part in the 33rd International Scientific Conference & 51st AGM of the Obstetrical and Gynaecological Society of Bangladesh (OGSB), held on 1–2 August 2025 at Pan Pacific Sonargaon, Dhaka. The event brought together eminent clinicians, researchers, and healthcare professionals from across the country and abroad.As part of our

ZAS Corporation’s Dermatology Division recently organized a Continuing Medical Education (CME) program at BIDSA, focusing on “The Role of Adalimumab in Psoriasis Management.” The session brought together leading dermatology experts to discuss updated clinical guidelines, recent research findings, and practical experiences in using adalimumab to manage moderate to severe psoriasis. Participants engaged in an interactive

ZAS Corporation recently organized a series of training sessions across multiple hospitals, engaging ICU nurses on the safe and effective use of noradrenaline in critical care settings. The program focused on practical guidance, updated protocols, and real-world application to support better patient outcomes. Through these interactive sessions, ZAS continues its commitment to enhancing clinical excellence